KKR Closes $4 Billion Health Care Strategic Growth Fund II
Posted on 01/10/2022
Private equity firm KKR announced the final closing of KKR Health Care Strategic Growth Fund II (HCSG II), a US$ 4 billion fund dedicated to health care growth equity investment opportunities primarily in North America and Europe.
HCSG II is the successor fund to KKR Health Care Strategic Growth Fund, KKR’s first dedicated health care growth equity vehicle, which held its final closing in November 2017 on US$ 1.45 billion in capital commitments. Similar to its predecessor fund, HCSG II will aim to generate strong returns for clients by investing in innovative health care companies with proven products and services that are seeking a partner to commercialize and scale. With a diversified portfolio approach, HCSG II will focus on the biopharmaceutical, medical device, health care services, life science tools / diagnostics, and health care information technology sub-sectors.
HCSG II received support from both new and existing investors globally, including public pension plans, sovereign wealth funds, insurance companies, financial institutions, endowments, private wealth and fintech platforms, family offices, and high-net-worth individual investors. KKR will be investing approximately US$ 500 million of capital in the Fund alongside these investors through the Firm’s balance sheet, affiliates, and employee commitments.
In 2021, KKR executed a number of new investments as part of its Health Care Strategic Growth initiatives, including in Argenta, Nordic Bioscience, Sapphiros, Geode Health, and Cordis.
